查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1438192

至 2030 年炭疽菌疫苗市场预测：按疫苗类型、类型、适应症、年龄层、应用、最终用户和地区进行的全球分析

Anthrax Vaccine Market Forecasts to 2030 - Global Analysis By Vaccine Type (Live Attenuated Vaccine, Cell Free PA Vaccine and Other Vaccine Types), Type, Disease Indication, Age Group, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球炭疽菌疫苗市场规模为 129 亿美元，预计在预测期内将以 6.5% 的复合年增长率增长，到 2030 年达到 202 亿美元。

炭疽菌疫苗是一种预防措施，旨在保护个人免受炭疽菌的侵害，这是一种由炭疽菌引起的严重细菌感染疾病。炭疽菌可以透过三种型态传播给人类和其他动物：皮肤、吸入和胃肠道。这种疫苗的开发主要是为了保护军事相关人员、实验室工作人员和接触炭疽菌孢子的高风险族群。此疫苗刺激免疫系统产生针对炭疽菌的保护性抗原成分的抗体。

根据 2021 年 4 月《兽医世界杂誌》发表的一篇论文，使用固定效应模型从 2452 个样本中得出，全球炭疽菌盛行率为 28%。在一项随机效应模型大陆研究中，非洲炭疽菌流行率最高（29%），北美最低（21%）。

炭疽菌流行率增加

炭疽菌市场的盛行率显着上升，反映出人们对炭疽菌相关风险的日益关注。这种增长增加了对有效疫苗的需求，并刺激了研究和开发的进展。炭疽菌疫情的不断上升凸显了采取全面疫苗接种策略并推动市场成长和创新的必要性。然而，对炭疽菌的认识和教育对于公众健康至关重要，这是推动市场成长的一个因素。

副作用和安全问题

虽然炭疽菌疫苗能有效预防炭疽菌，但它会引起轻微至中度的副作用，例如注射部位疼痛、肿胀和发红。有些人可能会出现发烧、肌肉酸痛和疲劳。严重的过敏反应很少见，但也有可能发生。儘管安全问题包括不利事件的报告，但整体风险效益状况支持其在接触炭疽菌的高风险族群中使用。这些都是阻碍市场成长的因素。

技术进步

结合创新的递送系统和佐剂的下一代疫苗的开发提高了功效和安全性，并且市场正在经历重大的技术进步。先进的生物技术方法，例如重组 DNA 技术，被用来生产更有效和可扩展的疫苗。此外，配方技术和储存技术的进步有助于提高稳定性和易于分配。

製造成本高

复杂的製造流程、严格的品管措施以及对专业设施的需求导致了高成本。高昂的製造成本不仅影响了疫苗的承受能力，而且对市场准入和广泛分发构成了挑战，限制了疫苗向更广泛人群的可用性。解决这些与成本相关的障碍对于提高炭疽菌疫苗的可用性和可近性至关重要。这些因素正在阻碍因素市场成长。

COVID-19 的影响：

COVID-19 大流行透过医疗保健优先事项和资源的变化间接影响市场。由于注意力和资金被转移到对抗这场流行病上，炭疽菌的研究和发展可能已被推迟。此外，供应链和医疗保健系统的中断可能会影响製造和分销。然而，人们对公共卫生和生物防御的兴趣日益浓厚，凸显了炭疽菌疫苗的重要性，并可能导致人们对疫情后情势的认识和投资增加。

减毒活病毒疫苗预计将在预测期内成为最大的部分

减毒活病毒疫苗预计将成为预测期内最大的部分。减毒活病毒疫苗炭疽菌疫苗正成为市场上一种有前景的疫苗接种方法。这些疫苗使用减毒版炭疽菌疫苗，可刺激强大的免疫反应，而不会引起疾病。在炭疽菌疫苗市场，由于减毒活病毒疫苗能够维持长期免疫力，其需求正快速增加。

预计製药业在预测期内复合年增长率最高

预计製药业在预测期内的复合年增长率最高。这些设施作为炭疽菌疫苗的分发中心，使个人和医疗保健提供者更容易购买所需的剂量。药房还透过提供有关疫苗接种时间表、潜在副作用和正确管理的资讯和指导，为公共卫生做出贡献。药房参与炭疽菌疫苗市场提高了疫苗的整体供应量，并促进了社区对这种严重感染疾病的保护。

比最大的地区

预计北美在预测期内将占据最大的市场占有率。该地区强大的医疗基础设施和对生物恐怖主义威胁的日益认识正在促进市场扩张。市场主要参与者积极从事研发，以提高疫苗的有效性，进而提高市场竞争力。此外，製药公司和政府机构之间的策略联盟正在进一步推动市场动态，并确保炭疽菌疫苗需求的稳定成长。

复合年增长率最高的地区：

预计亚太地区在预测期内将维持最高的复合年增长率。政府促进疫苗接种的努力和医疗基础设施的进步正在促进市场扩张。该地区的主要公司正在专注于研究和开发，以提高疫苗的有效性。对公共卫生措施和生物恐怖主义事件防备的日益重视也推动了该地区对炭疽菌疫苗的需求。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球炭疽菌疫苗市场：依疫苗类型

  • 减毒活病毒疫苗
  • 无细胞PA疫苗
    • 吸收性炭疽菌疫苗 (AVA)
    • 沉淀炭疽菌疫苗 (AVP)
  • 其他的

第六章全球炭疽菌疫苗市场：依类型

  • 次单位疫苗
    • 类毒素疫苗
    • 结合疫苗
    • 重组疫苗
  • 病毒载体疫苗
  • 其他的

第七章全球炭疽菌疫苗市场：依适应症分类

  • 病毒性疾病
    • 流感
    • 肝炎
    • 带状疱疹
    • 轮状病毒
    • 其他的
  • 细菌疫苗
    • 肺炎球菌疾病
    • 脑膜炎球菌疾病
    • 细菌疫苗
  • 其他的

第八章全球炭疽菌疫苗市场：依年龄组别

  • 成人
  • 儿童

第九章全球炭疽菌疫苗市场：依应用分类

  • 对于人类
  • 对于动物
  • 其他的

第10章全球炭疽菌疫苗市场：依最终用户分类

  • 药局
  • 医院
  • 其他的

第十一章全球炭疽菌疫苗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司简介

  • AstraZeneca
  • BioNTech SE
  • Colondo Serum Company
  • Emergent Bio Solutions
  • Merck & Co., Inc
  • Moderna Inc.
  • Pfizer Inc
  • Proton Biopharma Ltd
  • Sanofi
  • Seqirus
  • Serum Institute of India Pvt. Ltd
  • ICON plc
Product Code: SMRC25161

According to Stratistics MRC, the Global Anthrax Vaccine Market is accounted for $12.9 billion in 2023 and is expected to reach $20.2 billion by 2030 growing at a CAGR of 6.5% during the forecast period. The Anthrax vaccine is a preventive measure designed to protect individuals from anthrax, a potentially serious bacterial infection caused by the bacterium Bacillus anthracis. Anthrax can affect humans and other animals, and it can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. The vaccine is primarily developed to safeguard military personnel, laboratory workers, and individuals at high risk of exposure to anthrax spores. The vaccine stimulates the immune system to produce antibodies against the protective antigen component of the bacillus anthracis bacterium.

According to an article published in the Veterinary World Journal in April 2021, the prevalence of anthrax globally was 28% from 2452 samples through the fixed effects model. The random effects model's continent-by-subgroup study showed that the pooled prevalence of anthrax was highest in Africa (29%) and lowest in North America (21%).

Market Dynamics:

Driver:

Increase in prevalence of anthrax

The market has witnessed a notable surge in prevalence, reflecting a growing concern for anthrax-related risks. This upswing has heightened demand for effective vaccines, prompting advancements in research and development. The increasing prevalence of anthrax underscores the imperative for comprehensive vaccination strategies, driving market growth and innovation. However, increasing awareness and education about anthrax vaccines is paramount for public health is the factor propelling the growth of the market.

Restraint:

Side effects and safety concerns

The anthrax vaccine, while effective in preventing anthrax, may cause mild to moderate side effects such as pain, swelling, or redness at the injection site. Some individuals may experience fever, muscle aches, or fatigue. Severe allergic reactions are rare but possible. Safety concerns include reports of adverse events, though the overall risk-benefit profile supports its use for those at high risk of anthrax exposure. These are the factors hampering the growth of the market.

Opportunity:

Technological advancements

The market has witnessed significant technological advancements, with the development of next-generation vaccines incorporating innovative delivery systems and adjuvant to enhance efficacy and safety. Advanced biotechnological methods, such as recombinant DNA technology, have been employed to produce more effective and scalable vaccines. Additionally, advancements in formulation and storage technologies contribute to improved stability and ease of distribution.

Threat:

High manufacturing costs

The complex production process, stringent quality control measures, and the need for specialized facilities contribute to elevated expenses. These high manufacturing costs not only impact the affordability of the vaccine but also pose challenges for market accessibility and widespread distribution, limiting its availability to a broader population. Addressing these cost-related barriers is crucial for enhancing the affordability and accessibility of anthrax vaccines. These are the factors hindering the growth of the market.

Covid-19 Impact:

The COVID-19 pandemic has indirectly impacted the market, with shifts in healthcare priorities and resources. Attention and funding diverted to combat the pandemic may have slowed Anthrax vaccine research and development. Additionally, disruptions in supply chains and healthcare systems could affect manufacturing and distribution. However, the heightened focus on public health and biodefense may underscore the importance of anthrax vaccines, potentially leading to increased awareness and investment in the post-pandemic landscape.

The live attenuated vaccine segment is expected to be the largest during the forecast period

The live attenuated vaccine segment is expected to be the largest during the forecast period. Live attenuated vaccines for anthrax have gained prominence in the market, offering a promising approach to immunization. Leveraging weakened forms of the anthrax bacterium, these vaccines stimulate a robust immune response without causing the disease. The market for anthrax vaccines is witnessing a notable surge in demand for live attenuated options due to their efficacy in conferring long-lasting immunity.

The pharmacies segment is expected to have the highest CAGR during the forecast period

The pharmacies segment is expected to have the highest CAGR during the forecast period. These establishments serve as distribution points for anthrax vaccines, ensuring that individuals and healthcare providers can easily procure the necessary doses. Pharmacies also contribute to public health by offering information and guidance on vaccination schedules, potential side effects, and proper administration. Their involvement in the Anthrax Vaccine market enhances overall vaccine availability and promotes community protection against this serious infectious disease.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The region's robust healthcare infrastructure and rising awareness regarding bioterrorism threats contribute to market expansion. Key market players are actively engaged in research and development to enhance vaccine efficacy, fostering market competitiveness. Additionally, strategic collaborations between pharmaceutical companies and government bodies further propel market dynamics, ensuring a steady surge in demand for anthrax vaccines.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. Government initiatives promoting vaccination, coupled with advancements in healthcare infrastructure, contribute to market expansion. Key players in the region are focusing on research and development to enhance vaccine efficacy. The growing emphasis on public health measures and preparedness against bioterrorism incidents further propels the demand for anthrax vaccines in the region.

Key players in the market

Some of the key players in Anthrax Vaccine market include AstraZeneca, BioNTech SE, Colondo Serum Company, Emergent Bio Solutions, Merck & Co., Inc, Moderna Inc., Pfizer Inc, Proton Biopharma Ltd, Sanofi, Seqirus, Serum Institute of India Pvt. Ltd and ICON plc.

Key Developments:

In October 2022, ICON plc was selected by the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS), to execute an anthrax vaccine clinical trial. The Anthrax vaccine AV7909 is currently under clinical trial evaluation.

In June 2022, Emergent BioSolutions Inc. was granted review acceptance of the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) from the US FDA. AV7909 is evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in adults (age group 18 - 65). The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in April 2023.

Vaccine Types Covered:

  • Live Attenuated Vaccine
  • Cell Free PA Vaccine
  • Other Vaccine Types

Types Covered:

  • Subunit Vaccines
  • Viral Vector Vaccines
  • Other Types

Disease Indications Covered:

  • Viral Disease
  • Bacterial Vaccine
  • Other Disease Indications

Age Groups Covered:

  • Adult
  • Pediatric

Applications Covered:

  • Human Use
  • Animal Use
  • Other Applications

End Users Covered:

  • Pharmacies
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Anthrax Vaccine Market, By Vaccine Type

  • 5.1 Introduction
  • 5.2 Live Attenuated Vaccine
  • 5.3 Cell Free PA Vaccine
    • 5.3.1 Anthrax Vaccine Absorbed (AVA)
    • 5.3.2 Anthrax Vaccine Precipitated (AVP)
  • 5.4 Other Vaccine Types

6 Global Anthrax Vaccine Market, By Type

  • 6.1 Introduction
  • 6.2 Subunit Vaccines
    • 6.2.1 Toxoid Vaccines
    • 6.2.2 Conjugate Vaccines
    • 6.2.3 Recombinant vaccines
  • 6.3 Viral Vector Vaccines
  • 6.4 Other Types

7 Global Anthrax Vaccine Market, By Disease Indication

  • 7.1 Introduction
  • 7.2 Viral Disease
    • 7.2.1 Influenza
    • 7.2.2 Hepatitis
    • 7.2.3 Herpes Zoster
    • 7.2.4 Rotavirus
    • 7.2.5 Other Viral Diseases
  • 7.3 Bacterial Vaccine
    • 7.3.1 Pneumococcal Diseases
    • 7.3.2 Meningococcal Diseases
    • 7.3.3 Bacterial Vaccines
  • 7.4 Other Disease Indications

8 Global Anthrax Vaccine Market, By Age Group

  • 8.1 Introduction
  • 8.2 Adult
  • 8.3 Pediatric

9 Global Anthrax Vaccine Market, By Application

  • 9.1 Introduction
  • 9.2 Human Use
  • 9.3 Animal Use
  • 9.4 Other Applications

10 Global Anthrax Vaccine Market, By End User

  • 10.1 Introduction
  • 10.2 Pharmacies
  • 10.3 Hospitals
  • 10.4 Other End Users

11 Global Anthrax Vaccine Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 AstraZeneca
  • 13.2 BioNTech SE
  • 13.3 Colondo Serum Company
  • 13.4 Emergent Bio Solutions
  • 13.5 Merck & Co., Inc
  • 13.6 Moderna Inc.
  • 13.7 Pfizer Inc
  • 13.8 Proton Biopharma Ltd
  • 13.9 Sanofi
  • 13.10 Seqirus
  • 13.11 Serum Institute of India Pvt. Ltd
  • 13.12 ICON plc

List of Tables

  • Table 1 Global Anthrax Vaccine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Anthrax Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 3 Global Anthrax Vaccine Market Outlook, By Live Attenuated Vaccine (2021-2030) ($MN)
  • Table 4 Global Anthrax Vaccine Market Outlook, By Cell Free PA Vaccine (2021-2030) ($MN)
  • Table 5 Global Anthrax Vaccine Market Outlook, By Anthrax Vaccine Absorbed (AVA) (2021-2030) ($MN)
  • Table 6 Global Anthrax Vaccine Market Outlook, By Anthrax Vaccine Precipitated (AVP) (2021-2030) ($MN)
  • Table 7 Global Anthrax Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 8 Global Anthrax Vaccine Market Outlook, By Type (2021-2030) ($MN)
  • Table 9 Global Anthrax Vaccine Market Outlook, By Subunit Vaccines (2021-2030) ($MN)
  • Table 10 Global Anthrax Vaccine Market Outlook, By Toxoid Vaccines (2021-2030) ($MN)
  • Table 11 Global Anthrax Vaccine Market Outlook, By Conjugate Vaccines (2021-2030) ($MN)
  • Table 12 Global Anthrax Vaccine Market Outlook, By Recombinant vaccines (2021-2030) ($MN)
  • Table 13 Global Anthrax Vaccine Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 14 Global Anthrax Vaccine Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 15 Global Anthrax Vaccine Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 16 Global Anthrax Vaccine Market Outlook, By Viral Disease (2021-2030) ($MN)
  • Table 17 Global Anthrax Vaccine Market Outlook, By Influenza (2021-2030) ($MN)
  • Table 18 Global Anthrax Vaccine Market Outlook, By Hepatitis (2021-2030) ($MN)
  • Table 19 Global Anthrax Vaccine Market Outlook, By Herpes Zoster (2021-2030) ($MN)
  • Table 20 Global Anthrax Vaccine Market Outlook, By Rotavirus (2021-2030) ($MN)
  • Table 21 Global Anthrax Vaccine Market Outlook, By Other Viral Diseases (2021-2030) ($MN)
  • Table 22 Global Anthrax Vaccine Market Outlook, By Bacterial Vaccine (2021-2030) ($MN)
  • Table 23 Global Anthrax Vaccine Market Outlook, By Pneumococcal Diseases (2021-2030) ($MN)
  • Table 24 Global Anthrax Vaccine Market Outlook, By Meningococcal Diseases (2021-2030) ($MN)
  • Table 25 Global Anthrax Vaccine Market Outlook, By Bacterial Vaccines (2021-2030) ($MN)
  • Table 26 Global Anthrax Vaccine Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 27 Global Anthrax Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 28 Global Anthrax Vaccine Market Outlook, By Adult (2021-2030) ($MN)
  • Table 29 Global Anthrax Vaccine Market Outlook, By Pediatric (2021-2030) ($MN)
  • Table 30 Global Anthrax Vaccine Market Outlook, By Application (2021-2030) ($MN)
  • Table 31 Global Anthrax Vaccine Market Outlook, By Human Use (2021-2030) ($MN)
  • Table 32 Global Anthrax Vaccine Market Outlook, By Animal Use (2021-2030) ($MN)
  • Table 33 Global Anthrax Vaccine Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 34 Global Anthrax Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 Global Anthrax Vaccine Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 36 Global Anthrax Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 37 Global Anthrax Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.